Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011)
Biogen (BIIB) posted quarterly Current Deferred Tax Assets of $8.1 million for Q4 2011, down 92.78% year-over-year from $112.2 million in Q4 2010, and down 92.78% quarter-over-quarter from $112.2 million in Q4 2010.
Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011) Analysis & Trends
Biogen's Current Deferred Tax Assets history runs 2 years deep, the most recent figure standing at $8.1 million for Q4 2011.
- In Q4 2011, Current Deferred Tax Assets fell 92.78% year-over-year to $8.1 million; the TTM figure through Dec 2011 stood at $8.1 million (down 92.78% YoY), while the FY2011 annual figure was $8.1 million, down 92.78% from the prior year.
- Current Deferred Tax Assets for Q4 2011 stood at $8.1 million, down from $112.2 million in the prior quarter.
- The five-year high for Current Deferred Tax Assets was $112.2 million in Q4 2010, with the low at $8.1 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 8.10 Mn |
| Dec 31, 2011 | 8.10 Mn |
| Dec 31, 2010 | 112.20 Mn |
| Dec 31, 2010 | 112.20 Mn |